首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Cancer Treatment Reviews

Cancer Treatment Reviews杂志,由W.B. Saunders Ltd出版,于1974年创刊,Quarterly,出版语言English,ISSN:0305-7372,E-ISSN:1532-1967。

投稿咨询
Cancer Treatment Reviews
Cancer Treatment Reviews
Cancer Treatment Reviews
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
10.6
CiteScore
17.7
期刊收录
SCI、SCIE

Cancer Treatment Reviews(中文译名:《癌症治疗评论》),ISSN:0305-7372,EISSN:1532-1967,是W.B. Saunders Ltd出版的国际性学术期刊,创刊于1974年,以Quarterly形式稳定发行,2026年总发文量约118篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达10.6,2025年期刊CiteScore为17.7,2025年期刊自引率约0.9%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Cancer Treatment Reviews长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期约6月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,ItalyUSA、England、Spain、France、Netherlands、GERMANY (FED REP GER)等为核心发文国家与地区;UNICANCERUNIVERSITY OF MILAN、UNIVERSITY OF TORONTO、UNIVERSITY OF TEXAS SYSTEM、CIBER - CENTRO DE INVESTIGACION BIOMEDICA EN RED、FONDAZIONE IRCCS ISTITUTO NAZIONALE TUMORI MILAN、IRCCS EUROPEAN INSTITUTE OF ONCOLOGY (IEO)等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
2区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
2区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
2区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 34 / 333

89.9

学科:ONCOLOGY SCIE Q1 53 / 333

84.23

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 28 / 328

91.6

学科:ONCOLOGY SCIE Q1 46 / 328

86.13


中国学者近期发文

1
Neoantigen-based dendritic cell vaccines in lung cancer: overcoming immunosuppressive barriers for durable antitumor immunit

Author:Li, Zhang; Zhang, Feiyue; Luyu, Huang; Zhang, Wenqiang; Ismail, Mahmoud; Rueckert, Jens-C

Journal: CANCER TREATMENT REVIEWS. 2026; Vol. 145, Issue , pp. -. DOI: 10.1016/j.ctrv.2026.103125

2
Circulating tumor DNA in breast cancer: From technological foundation to clinical implementatio

Author:Lin, Xinyi; Liu, Baiying; Wu, Jing; Shi, Lina; Zhang, Yanyan; Yang, Qiaoyu; Tang, Haiyun; Xu, Shaoting; Gao, Yuxuan; Cui, Jihong; Zhang, Yunjian

Journal: CANCER TREATMENT REVIEWS. 2026; Vol. 144, Issue , pp. -. DOI: 10.1016/j.ctrv.2026.103108

3
Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody-Drug conjugate

Author:Li, Yuwei; Chen, Kaiyan; Li, Hui; Fan, Yun

Journal: CANCER TREATMENT REVIEWS. 2026; Vol. 143, Issue , pp. -. DOI: 10.1016/j.ctrv.2026.103091

4
Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far

Author:Cheo, Seng Wee; Li, Molly S. C.; Huang, Derek De-Rui; Saw, Stephanie P. L.; Hendriks, Lizza E. L.; Remon, Jordi; Menis, Jessica; Addeo, Alfredo; Voon, Pei Jye

Journal: CANCER TREATMENT REVIEWS. 2026; Vol. 143, Issue , pp. -. DOI: 10.1016/j.ctrv.2025.103083

5
Long and short-term efficacy and safety comparison of nab-paclitaxel versus paclitaxel combined with trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer: A systematic review and meta-analysi

Author:Yuan, Ye; Long, Xin; Wei, Mengya; Chen, Li; Zhang, Ji; Liu, Xumei

Journal: CANCER TREATMENT REVIEWS. 2025; Vol. 138, Issue , pp. -. DOI: 10.1016/j.ctrv.2025.102975

6
Chimeric antigen receptor NK cells for breast cancer immunotherap

Author:Wu, Nisha; Yang, Ning; Zhang, Shiqi; Wu, Haoran; Fang, Xuechun; Lin, Wanying; Zhang, Yi; Qi, Xiaowei; Gong, Ying

Journal: CANCER TREATMENT REVIEWS. 2025; Vol. 137, Issue , pp. -. DOI: 10.1016/j.ctrv.2025.102943

7
Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 immunotherap

Author:Tahara, Makoto; Lim, Darren Wan-Teck; Keam, Bhumsuk; Ma, Brigette; Zhang, Li; Wang, Chaojun; Guo, Ye

Journal: CANCER TREATMENT REVIEWS. 2025; Vol. 136, Issue , pp. -. DOI: 10.1016/j.ctrv.2025.102938

8
Operationalizing intermediate clinical endpoints: A pragmatic framework for prostate cancer management trial

Author:Xiong, Xingyu; Zhang, Shiyu; Du, Jiajia; Liao, Xinyang; Yang, Jie; Zheng, Weitao; Xu, Hang; Yang, Lu; Wei, Qiang

Journal: CANCER TREATMENT REVIEWS. 2025; Vol. 136, Issue , pp. -. DOI: 10.1016/j.ctrv.2025.102935

9
Managing strategies of chemotherapy and radiotherapy-induced oral mucositi

Author:Wu, Yuqi; Shi, Wenjin; Li, Chunyu; Liu, Xiangfei; Jiang, Yuchen; Qiu, Yan; Chen, Qianming; Luo, Xiaobo

Journal: CANCER TREATMENT REVIEWS. 2025; Vol. 133, Issue , pp. -. DOI: 10.1016/j.ctrv.2025.102883

10
Incomplete ovarian function suppression in premenopausal breast cancer patients treated with gonadotropin-releasing hormone agonist

Author:Lin, Jinna; Zheng, Shuqi; Liu, Qiang

Journal: CANCER TREATMENT REVIEWS. 2025; Vol. 133, Issue , pp. -. DOI: 10.1016/j.ctrv.2025.102879


在线咨询

Cancer Treatment Reviews

国际简称:CANCER TREAT REV参考译名:癌症治疗评论

年发文量:118 CiteScore:17.7 是否预警:否 Gold OA文章占比:37.12% 研究类文章占比:0.00%

杂志社联系方式:ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND, OXON, OX5 1GB

Cancer Treatment Reviews